Abstract 334P
Background
Immune checkpoint inhibitors (ICI) have been approved for non-small lung cancer (NSCLC). Adrenal insufficiency (AI) is a distinctive adverse event related to ICI. This can be either primary adrenal gland destruction or interference with corticotrophin (ACTH) secretion by the pituitary gland (secondary). As AI is relatively rare and symptoms and signs of AI are non-specific, the diagnosis of AI is often difficult. To clear the incidence and characteristics of AI related with ICI. We conducted a retrospective single center study.
Methods
We reviewed the medical records of patients with NSCLC who received pembrolizumab, nivolumab, atezolizumab or duravalmab at JCHO Kyushu Hospital between Feb 2017 and Jun 2019.
Results
A total of 114 patients with NSCLC received ICI. Eight patients (7.0%) were diagnosed with AI. Median age was 67 (range: 54 to 79). Six were male. Six out of eight patients were secondary AI, one patient was primary AI, and one patient was unknown. The median onset of AI from the first dose of ICI was 203 days (range: 38 to 763). The patients presented with fatigue, fever, nausea, diarrhea and/or dizziness. One patient was diagnosed because of repeating COPD/asthma attack. Hypocholesterolemia, hyponatremia, eosinophilia, hypoglycemia, and hyperkalemia were found 4, 2, 3, 1 and 1 out of 8 patients respectively. One patient didn’t exhibit any above symptom. All of the patients had rapid resolution of symptoms after hydrocortisone replacement.
Conclusions
ICI-associated AI developed in 7.0% of patients requiring hydrocortisone replacement therapy. Symptoms and laboratory abnormalities at the time of onset varied. It is thought that patients using ICI therapy will further increase in the future, and patients who develop ICI-related AI will also increase. Clinicians should deepen their understanding of the nature of AI and provide appropriate information to patients so that AI can be quickly diagnosed and treated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract